H. Schmoll

Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.

M. Aapro, H. Schmoll, F. Jahn, 2013, Cancer treatment reviews.

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

F. Lordick, T. Seufferlein, A. Zubel, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study

W. Voigt, D. Arnold, H. Wolf, 2010, Bone Marrow Transplantation.

Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer.

W. Voigt, H. Schmoll, K. Jordan, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).

T. Gauler, A. Karch, V. Grünwald, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

J Schleicher, C. Bokemeyer, L. Kanz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

S. Litière, J. Bogaerts, Y. Ohe, 2016, ESMO Open.

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials

S. Lonardi, A. Sobrero, I. Souglakos, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The evolution of fluoropyrimidine therapy: from intravenous to oral.

J. Cassidy, P. Hoff, H. Schmoll, 2001, The oncologist.

Where do we stand with 5-fluorouracil?

A. Grothey, W. Dempke, H. Schmoll, 1999, Seminars in oncology.